Keep pulling the thread on Martin Shkreli.
Martin Shkreli believes AI has little to contribute to drug discovery because the primary bottleneck is identifying the correct biological target, not the subsequent chemistry or antibody creation which he considers relatively easy.
Martin Shkreli believes the most valuable use of AI in pharma would be an LLM that reads all 38 million papers in the PubMed database to identify novel drug targets.
Martin Shkreli is legally banned from participating in the U.S. pharmaceutical industry.
Sam Bankman-Fried was sentenced to 25 years in prison.
Martin Shkreli predicts that OpenAI will eventually go public with a market capitalization of $1 trillion.
Vivek Ramaswamy was Martin Shkreli's first investor in his pharmaceutical ventures.
Martin Shkreli views the pharmaceutical industry as a fragmented, modular business where individual drugs are very similar, making it ripe for arbitrage, unlike the more differentiated software industry.
Martin Shkreli co-developed a drug concept for a rare pediatric disease where children lack the panothenic kinase enzyme, which is needed to process vitamin B5.
Martin Shkreli asserts that for orphan drugs targeting diseases with very small patient populations, such as 500 people, a price of a million dollars per patient is necessary to make development economically viable.
The co-founders of Rippling, Replit, and Flexport were pre-seed investors in Martin Shkreli's current company, influenced by his educational live-streamed videos.
The drug for toxoplasmosis, whose price Martin Shkreli's company increased, was approximately 70 years old and no improved version had been developed in that time.
Chagas disease, a condition prevalent in Latin America, currently has no FDA-approved drug treatment.